XG-004 is under clinical development by Xgene Pharmaceutical and currently in Phase II for Osteoarthritis Pain. According to GlobalData, Phase II drugs for Osteoarthritis Pain have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XG-004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XG-004 overview
XG-004 is under development for the treatment of osteoarthritis pain. The drug candidate is a conjugate of naproxen and pregabalin. It is administered through transdermal route. Naproxen acts by targeting COX1 and COX2 whereas pregabalin acts by targeting voltage-dependent calcium channel subunit alpha2/delta1 and delta 2.
Xgene Pharmaceutical overview
Xgene Pharmaceutical is a clinical stage healthcare and pharmaceutical company. The company pipeline product include XG005-02, XG005-03, XG004-03 and XG043 among others. It’s XG005-02 products is in US Phase III studies in treatment of acute pain. The company discovers and develops novel small-molecule drugs for chronic pain, tumors and infectious diseases. Xgene Pharmaceutical serves its product in gels, oral tablets and others. Xgene Pharmaceutical also invests in drug development programs targeting acute, chronic pain, cluster headache, dizziness, sleeplessness, confusion and others. The company operates in Taiwan and China. Xgene Pharmaceutical is headquartered in Jing An, Shanghai, China.
For a complete picture of XG-004’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
